Prostate cancer trials in France

In France 109 Also abroad 1480

109 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Where
Montpellier, Villejuif
Age
18 years and over
People
54 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07332455
Phase 2Taking people
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Bordeaux, Lyon, Marseille, Paris, Villejuif
Age
18 years and over
People
100 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07287150 · EU 2025-521327-67-00
Phase 3Taking people
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Where
Bayonne, Clermont Ferrand Cedex1, Lille, Nîmes, Paris, Rennes Cedex, Strasbourg Cedex 2, Villejuif
Age
18 years and over
People
1,310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00
Phase 4Not yet taking people in France
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
Where
Toulouse
Age
70 years and over
People
30
Run by
University Hospital, Toulouse
See details and how to joinNCT07766122 · EU 2026-525181-22-00
Phase 3Taking people
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
Where
Nancy
Age
18 years and over
People
434 worldwide
Run by
ABX advanced biochemical compounds GmbH
See details and how to joinNCT06122584
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Villejuif
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Lille, Marseille, Nantes, Paris, Toulouse, Villejuif
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 1Taking people
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Where
Paris, Saint-Herblain
Age
18 years and over
People
421 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00
Phase 1Taking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Where
Lyon, Marseille, Villejuif
Age
18 years and over
People
210 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT05800665 · EU 2023-504013-68-00
Phase 1Taking people
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Where
Bordeaux, Lyon, Villejuif
Age
18 years and over
People
355 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06095089 · EU 2023-504063-17-00
Phase 3Taking people
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Where
Bordeaux, Brest, Dijon, Lille, Lyon, Paris, Pierre-Bénite, Saint-Herblain Cedex, Strasbourg Cedex 2, Toulouse, Vandoeuvre Les Nancy_ Cedex, Villejuif
Age
18 years and over
People
1,203 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00
Phase 3Taking people
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Bordeaux, Clermont-Ferrand, Lille, Lyon, Nimes Cedex 9, Paris, Rennes Cedex, Villejuif
Age
18 years and over
People
800 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07225946 · EU 2025-522713-29-00
No phaseTaking people
A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France
Where
Caen
Age
18 years and over
People
540
Run by
Janssen Cilag S.A.S.
See details and how to joinNCT07451002
Phase 3Taking people
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Where
Bordeaux, Brest, Clermont Ferrand Cedex1, Le Mans, Lyon, Pierre-Bénite, Reims, Saint-Grégoire, Saint-Herblain Cedex, Strasbourg
Age
18 years and over
People
900 worldwide
Run by
Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00
Phase 3Taking people
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Where
Caen Cedex 5, Limoges Cedex I, Marseille, Nimes Cedex 9, Paris, Rouen Cedex, Strasbourg Cedex 2, Suresnes, Vandoeuvre Les Nancy_ Cedex
Age
18 years and over
People
1,440 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00
Phase 1/2Taking people
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Where
Pierre-Bénite
Age
18 years and over
People
160 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00
Phase 1/2Taking people
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Where
Pierre-Bénite
Age
18 years and over
People
205 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07288359
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1Taking people
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Where
Lille, Lyon
Age
18 years and over
People
60 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07244341 · EU 2025-522512-16-00
Phase 1Taking people
A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
Where
Bordeaux
Age
18 years and over
People
26 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-524080-20-00 · EU 2025-524080-20-00
Phase 1/2Taking people
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Where
Lyon, Montpellier, Saint-Herblain, Suresnes, Villejuif
Age
18 years to 130 years
People
283 worldwide
Run by
AstraZeneca
See details and how to joinNCT07181161 · EU 2024-520026-11-00
Phase 3Taking people
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Where
Angers, Bordeaux, Bron, Clermont-Ferrand, Paris, Rouen, Saint-Cloud, Saint-Herblain Cedex
Age
18 years to 100 years
People
450 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00
Phase 3Taking people
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Where
Bordeaux, Brest Cedex 2, Clermont Ferrand Cedex1, Lille, Lyon, Paris, Strasbourg Cedex 2, Suresnes, Villejuif
Age
18 years and over
People
1,314 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00
Phase 3Taking people
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Where
Bordeaux, Caen, Clermont-Ferrand, Le Mans, Lyon, Nice, Paris, Strasbourg, Suresnes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
18 years and over
People
750 worldwide
Run by
Amgen
See details and how to joinNCT07213674
No phaseTaking people
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
Where
Many Locations
Age
18 years and over
People
1,600 worldwide
Run by
Bayer
See details and how to joinNCT07344779